A Feasibility Study of Donepezil in Female Breast Cancer Survivors With Self-Reported Cognitive Dysfunction Following Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2016
At a glance
- Drugs Donepezil (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; Therapeutic Use
- 08 Jan 2015 Time frame for primary endpoint assessment has been changed from 36 weeks to 24 weeks as reported by ClinicalTrials.gov record.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov